Document Status

This document has been corrected

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

10.1093/annonc/mdv213

Published Online: 2015-07-?

Journal: Annals of Oncology•Publisher: Elsevier BV

Authors: D. Mavroudis•E. Saloustros•I. Boukovinas•N. Kentepozidis•N. Malamos•N. Ziras•P. Papakotoulas•S. Kakolyris•V. Georgoulias

This document has been corrected

10.1093/annonc/mdv213

Published Online: 2015-07-?

Journal: Annals of Oncology

Authors: D. Mavroudis•E. Saloustros•I. Boukovinas•N. Kentepozidis•N. Malamos•N. Ziras•P. Papakotoulas•S. Kakolyris•V. Georgoulias

NOW

2020-03-01•Erratum

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

10.1016/j.annonc.2020.01.004

* information provided by CrossRef

2020-03-01•Erratum

10.1016/j.annonc.2020.01.004

* information provided by CrossRef

2015-07-?•Published